CD4 and Autoimmunity: Autoimmunity occurs generally 16 months after the last alemtuzumab administration [67], reaching the peak in the third year after starting alemtuzumab treatment [33]: The development of autoantibodies occurs months to years after alemtuzumab administration because it requires CD4+ T-cell involvement, which regenerate only six months to three years after depletion, with a subsequent delay between B cell hyperreactivity and development of autoimmunity [49].